A recommendation to expand Medicare funded genetic testing for myeloproliferative neoplasms (MPN) has been made by the Medicare Services Advisory Committee (MSAC). The Committee decided at its November 2020 meeting to recommend additional genes be tested for after initial JAK2 V617F testing. MBS item 73325 currently provides for Janus kinase (JAK2) and myeloproliferative leukaemia (MPL) ...
New genetic testing for MPN gets Medicare tick of approval
By Mardi Chapman
11 Mar 2021